Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.

Barve A, Vega A, Shah PP, Ghare S, Casson L, Wunderlich M, Siskind LJ, Beverly LJ.

Cells. 2019 Oct 25;8(11). pii: E1322. doi: 10.3390/cells8111322.

2.

Moderate aging does not exacerbate cisplatin-induced kidney injury or fibrosis despite altered inflammatory cytokine expression and immune cell infiltration.

Sharp CN, Doll M, Dupre TV, Beverly LJ, Siskind LJ.

Am J Physiol Renal Physiol. 2019 Jan 1;316(1):F162-F172. doi: 10.1152/ajprenal.00463.2018. Epub 2018 Nov 28.

PMID:
30484347
3.

The role of sphingolipids in acute kidney injury.

Dupre TV, Siskind LJ.

Adv Biol Regul. 2018 Dec;70:31-39. doi: 10.1016/j.jbior.2018.11.003. Epub 2018 Nov 13. Review.

PMID:
30455062
4.

Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease.

Sharp CN, Doll MA, Megyesi J, Oropilla GB, Beverly LJ, Siskind LJ.

Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F161-F172. doi: 10.1152/ajprenal.00636.2017. Epub 2018 Jan 31.

5.

Neuraminidase activity mediates IL-6 production by activated lupus-prone mesangial cells.

Sundararaj K, Rodgers JI, Marimuthu S, Siskind LJ, Bruner E, Nowling TK.

Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F630-F642. doi: 10.1152/ajprenal.00421.2017. Epub 2017 Dec 20.

6.

Regulation of insulin-like growth factor receptors by Ubiquilin1.

Kurlawala Z, Dunaway R, Shah PP, Gosney JA, Siskind LJ, Ceresa BP, Beverly LJ.

Biochem J. 2017 Dec 6;474(24):4105-4118. doi: 10.1042/BCJ20170620.

7.

Developing better mouse models to study cisplatin-induced kidney injury.

Sharp CN, Siskind LJ.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F835-F841. doi: 10.1152/ajprenal.00285.2017. Epub 2017 Jul 19. Review.

8.

Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury.

Dupre TV, Doll MA, Shah PP, Sharp CN, Siow D, Megyesi J, Shayman J, Bielawska A, Bielawski J, Beverly LJ, Hernandez-Corbacho M, Clarke CJ, Snider AJ, Schnellmann RG, Obeid LM, Hannun YA, Siskind LJ.

J Lipid Res. 2017 Jul;58(7):1439-1452. doi: 10.1194/jlr.M076745. Epub 2017 May 10.

9.

Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress.

Shah PP, Dupre TV, Siskind LJ, Beverly LJ.

Oncotarget. 2017 Apr 4;8(14):22625-22639. doi: 10.18632/oncotarget.15150.

10.

Bridging translation for acute kidney injury with better preclinical modeling of human disease.

Skrypnyk NI, Siskind LJ, Faubel S, de Caestecker MP.

Am J Physiol Renal Physiol. 2016 May 15;310(10):F972-84. doi: 10.1152/ajprenal.00552.2015. Epub 2016 Mar 9. Review.

11.

Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death.

Sundaram K, Mather AR, Marimuthu S, Shah PP, Snider AJ, Obeid LM, Hannun YA, Beverly LJ, Siskind LJ.

Biochem J. 2016 Mar 15;473(6):743-55. doi: 10.1042/BJ20150586. Epub 2016 Jan 8.

12.

Repeated administration of low-dose cisplatin in mice induces fibrosis.

Sharp CN, Doll MA, Dupre TV, Shah PP, Subathra M, Siow D, Arteel GE, Megyesi J, Beverly LJ, Siskind LJ.

Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F560-8. doi: 10.1152/ajprenal.00512.2015. Epub 2016 Jan 6.

13.

Suramin protects from cisplatin-induced acute kidney injury.

Dupre TV, Doll MA, Shah PP, Sharp CN, Kiefer A, Scherzer MT, Saurabh K, Saforo D, Siow D, Casson L, Arteel GE, Jenson AB, Megyesi J, Schnellmann RG, Beverly LJ, Siskind LJ.

Am J Physiol Renal Physiol. 2016 Feb 1;310(3):F248-58. doi: 10.1152/ajprenal.00433.2015. Epub 2015 Dec 9.

14.

Ceramide channel: Structural basis for selective membrane targeting.

Perera MN, Ganesan V, Siskind LJ, Szulc ZM, Bielawska A, Bittman R, Colombini M.

Chem Phys Lipids. 2016 Jan;194:110-116. doi: 10.1016/j.chemphyslip.2015.09.007. Epub 2015 Sep 25.

15.

Fibroblast-Derived Extracellular Matrices: An Alternative Cell Culture System That Increases Metastatic Cellular Properties.

Scherzer MT, Waigel S, Donninger H, Arumugam V, Zacharias W, Clark G, Siskind LJ, Soucy P, Beverly L.

PLoS One. 2015 Sep 15;10(9):e0138065. doi: 10.1371/journal.pone.0138065. eCollection 2015.

16.

Ceramide channels: destabilization by Bcl-xL and role in apoptosis.

Chang KT, Anishkin A, Patwardhan GA, Beverly LJ, Siskind LJ, Colombini M.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt A):2374-84. doi: 10.1016/j.bbamem.2015.07.013. Epub 2015 Jul 26.

17.

Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells.

Subathra M, Korrapati M, Howell LA, Arthur JM, Shayman JA, Schnellmann RG, Siskind LJ.

Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F204-15. doi: 10.1152/ajprenal.00150.2015. Epub 2015 Jun 3.

18.

Sphingolipids and mitochondrial apoptosis.

Patwardhan GA, Beverly LJ, Siskind LJ.

J Bioenerg Biomembr. 2016 Apr;48(2):153-68. doi: 10.1007/s10863-015-9602-3. Review.

19.

Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis.

Nowling TK, Mather AR, Thiyagarajan T, Hernández-Corbacho MJ, Powers TW, Jones EE, Snider AJ, Oates JC, Drake RR, Siskind LJ.

J Am Soc Nephrol. 2015 Jun;26(6):1402-13. doi: 10.1681/ASN.2014050508. Epub 2014 Sep 30.

20.

Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.

Stathem M, Marimuthu S, O'Neal J, Rathmell JC, Chesney JA, Beverly LJ, Siskind LJ.

J Cell Biochem. 2015 Jan;116(1):67-80. doi: 10.1002/jcb.24943.

Supplemental Content

Loading ...
Support Center